Going Back to the Biology of FGF21: New Insights.
Journal
Trends in endocrinology and metabolism: TEM
ISSN: 1879-3061
Titre abrégé: Trends Endocrinol Metab
Pays: United States
ID NLM: 9001516
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
18
04
2019
revised:
29
05
2019
accepted:
30
05
2019
pubmed:
30
6
2019
medline:
28
7
2020
entrez:
29
6
2019
Statut:
ppublish
Résumé
Fibroblast growth factor 21 (FGF21) is a protein highly synthesized in the liver that exerts paracrine and endocrine control of many aspects of energy homeostasis in multiple tissues. In preclinical models of obesity and type 2 diabetes, treatment with FGF21 improves glucose homeostasis and promotes weight loss, and, as a result, FGF21 has attracted considerable attention as a therapeutic agent for the treatment of metabolic syndrome in humans. An improved understanding of the biological role of FGF21 may help to explain why its therapeutic potential in humans has not been fully realized. This review will cover the complexities in FGF21 biology in rodents and humans, with emphasis on its role in protection from central and peripheral facets of obesity.
Identifiants
pubmed: 31248786
pii: S1043-2760(19)30106-7
doi: 10.1016/j.tem.2019.05.007
pii:
doi:
Substances chimiques
KLB protein, human
0
Membrane Proteins
0
fibroblast growth factor 21
0
Fibroblast Growth Factors
62031-54-3
Klotho Proteins
EC 3.2.1.31
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
491-504Subventions
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/M001555/1
Pays : United Kingdom
Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.